If a product hides its formulator, skips third-party testing, or buries doses in a proprietary blend, treat its claims with skepticism
Endometrium: GLP-1 reduces fibrosis and inflammation, suggesting a protective role
Our findings are consistent with this, as they indicate an additive effect over SGLT2 inhibition alone, but a limited incremental benefit beyond GLP-1 RAs
As for the patient base, a recent report found that 75% of patients stop taking the medications within two years, although the report did not elaborate on the causes of this decline in use, which may be partially attributable to factors such as high costs and self-funding requirements
Research into these diseases is ongoing and is helping us gain a better understanding of disease-causing genetic variants